Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21701587 | 0.97 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21701591 | 0.89 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21701579 | 0.86 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21701474 | 0.81 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21683033 | 0.80 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21701581 | 0.79 | POLB (0.56) | ALDH1A1SMN1; SMN2HSD17B10KDM4EKMT2A | |
| SCHEMBL21701594 | 0.77 | F10 (0.57) | ALDH1A1SMN1; SMN2GAAKMT2ACYP3A4 | |
| SCHEMBL21683032 | 0.72 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL15528812 | 0.70 | MAPK1 (0.71) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA | |
| SCHEMBL21701478 | 0.70 | CYP1A2 (0.61) | ALDH1A1SMN1; SMN2HSD17B10KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | Sanford Burnham Prebys Medical Discovery Institute | 2022-03-03 | — | — | US | disclosed |
| EP-3833352-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | University of Central Florida Research Foundation, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | ANXA6, ANXA1, ANTXR2 | ALDH1A1 163/4885SMN1; SMN2 589/4885HSD17B10 2667/4885 |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | ENY2, ANTXR2, ALAD | ALDH1A1 1777/4885SMN1; SMN2 2909/4885HSD17B10 2329/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | ALDH1A1 538/4885SMN1; SMN2 785/4885HSD17B10 4175/4885 |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | SLC19A1, PNMT, SRM | ALDH1A1 538/4885SMN1; SMN2 785/4885HSD17B10 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.